288 related articles for article (PubMed ID: 28104680)
41. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
Parajuli S; Jug R; Ahmadi S; Jiang XS
Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
[TBL] [Abstract][Full Text] [Related]
42. Multiplatform molecular test performance in indeterminate thyroid nodules.
Lupo MA; Walts AE; Sistrunk JW; Giordano TJ; Sadow PM; Massoll N; Campbell R; Jackson SA; Toney N; Narick CM; Kumar G; Mireskandari A; Finkelstein SD; Bose S
Diagn Cytopathol; 2020 Dec; 48(12):1254-1264. PubMed ID: 32767735
[TBL] [Abstract][Full Text] [Related]
43. Outcomes of Indeterminate Thyroid Nodules Managed Nonoperatively after Molecular Testing.
Zhu CY; Donangelo I; Gupta D; Nguyen DT; Ochoa JE; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1240-e1247. PubMed ID: 33394039
[TBL] [Abstract][Full Text] [Related]
44. Utility of mutational analysis for risk stratification of indeterminate thyroid nodules in a real-world setting.
Torrecillas V; Sharma A; Neuberger K; Abraham D
Clin Endocrinol (Oxf); 2022 Apr; 96(4):637-645. PubMed ID: 34605038
[TBL] [Abstract][Full Text] [Related]
45. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
[TBL] [Abstract][Full Text] [Related]
46. Triage of the indeterminate thyroid aspirate: What are the options for the practicing cytopathologist?
Onenerk AM; Pusztaszeri MP; Canberk S; Faquin WC
Cancer Cytopathol; 2017 Jun; 125(S6):477-485. PubMed ID: 28609009
[TBL] [Abstract][Full Text] [Related]
47. Risk Stratification Study of Indeterminate Thyroid Nodules with a next-generation Sequencing Assay with Residual ThinPrep® Material.
Zhao H; Jing W; Li W; Zhang Z; Cao J; Zhao L; Sun Y; Wang C; Wang Y; Guo H
J Cancer; 2020; 11(24):7276-7282. PubMed ID: 33193891
[No Abstract] [Full Text] [Related]
48. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
[No Abstract] [Full Text] [Related]
49. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
50. Carbonic anhydrase 4 and crystallin α-B immunoreactivity may distinguish benign from malignant thyroid nodules in patients with indeterminate thyroid cytology.
Davidov T; Nagar M; Kierson M; Chekmareva M; Chen C; Lu SE; Lin Y; Chernyavsky V; Potdevin L; Arumugam D; Barnard N; Trooskin S
J Surg Res; 2014 Aug; 190(2):565-74. PubMed ID: 24880201
[TBL] [Abstract][Full Text] [Related]
51. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
Chiosea S; Hodak SP; Yip L; Abraham D; Baldwin C; Baloch Z; Gulec SA; Hannoush ZC; Haugen BR; Joseph L; Kargi AY; Khanafshar E; Livhits MJ; McIver B; Patel K; Patel SG; Randolph GW; Shaha AR; Sharma J; Stathatos N; van Zante A; Carty SE; Nikiforov YE; Nikiforova MN
J Clin Endocrinol Metab; 2023 Oct; 108(11):2999-3008. PubMed ID: 37071871
[TBL] [Abstract][Full Text] [Related]
52. Systematic Review and Meta-analysis of the Impact of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Cytological Diagnosis and Thyroid Cancer Prevalence.
Ruanpeng D; Cheungpasitporn W; Thongprayoon C; Hennessey JV; Shrestha RT
Endocr Pathol; 2019 Sep; 30(3):189-200. PubMed ID: 31338752
[TBL] [Abstract][Full Text] [Related]
53. Heterogeneity in Positive Predictive Value of RAS Mutations in Cytologically Indeterminate Thyroid Nodules.
Nabhan F; Porter K; Lupo MA; Randolph GW; Patel KN; Kloos RT
Thyroid; 2018 Jun; 28(6):729-738. PubMed ID: 29665745
[TBL] [Abstract][Full Text] [Related]
54. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
Wu H; Zhang B; Cai G; Li J; Gu X
PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
[TBL] [Abstract][Full Text] [Related]
55. A thyroid EIF1AX story: how clinical, cytologic, and molecular surveillance led to appropriate management.
Geisler DL; Karslioglu French E; Yip L; Nikiforova MN; Nikiforov YE; Schoedel KE; Seethala RR; Ohori NP
J Am Soc Cytopathol; 2023; 12(2):105-111. PubMed ID: 36504010
[TBL] [Abstract][Full Text] [Related]
56. Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.
DiGennaro C; Vahdatzad V; Jalali MS; Toumi A; Watson T; Gazelle GS; Mercaldo N; Lubitz CC
Thyroid; 2022 Oct; 32(10):1144-1157. PubMed ID: 35999710
[No Abstract] [Full Text] [Related]
57. Indeterminate nodules by the Bethesda system for reporting thyroid cytopathology in Israel: Frequency, and risk of malignancy after reclassification of follicular thyroid neoplasm with papillary-like features.
Rosenblum RC; Shtabsky A; Marmor S; Trejo L; Yaish I; Barnes S; Yehuda M; Stern N; Silman Z; Tordjman KM
Eur J Surg Oncol; 2019 Jul; 45(7):1182-1187. PubMed ID: 30928335
[TBL] [Abstract][Full Text] [Related]
58. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
Hang JF; Westra WH; Cooper DS; Ali SZ
Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
[TBL] [Abstract][Full Text] [Related]
59. Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP).
Strickland KC; Eszlinger M; Paschke R; Angell TE; Alexander EK; Marqusee E; Nehs MA; Jo VY; Lowe A; Vivero M; Hollowell M; Qian X; Wieczorek T; French CA; Teot LA; Cibas ES; Lindeman NI; Krane JF; Barletta JA
Endocr Pathol; 2018 Mar; 29(1):68-74. PubMed ID: 29396809
[TBL] [Abstract][Full Text] [Related]
60. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
